SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / November 30, 2016 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (Nasdaq: ALXN). Investors who purchased or otherwise acquired shares between February 10, 2014 and November 9, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the January 17, 2017 lead plaintiff motion deadline.

If you purchased shares of Alexion during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that Alexion made false and/or misleading statements and/or failed to disclose: that the Company employed improper sales practices with respect to its product Soliris; that the Company’s revenues from Soliris sales were unlikely to be sustainable; and that as a result of the above, Alexion’s public statements were materially false and misleading at all relevant times. On November 4, 2016, Alexion cancelled an appearance at the Credit Suisse Healthcare Conference. Following the cancellation, analysts noticed that the Company also failed to file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016. On November 9, 2016, Alexion announced that the Company would not be able to timely file its financial and operating results for the quarter ended September 30, 2016. When this information was released, shares of Alexion declined in value, causing investors serious harm.

If you wish to learn more about this lawsuit at no charge, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 450065